Centene obviously know what they doing by listing Revascor but it seems way to premature to me. A confirmatory trial for mucosal bleeding sponsored by Icahn has still to fulfil enrolment so far as I know.The trial results will not be known for at least 18 months after enrolment and then Revascor still has to be submitted for FDA approval. I think therefore it has more to do with the readout from the phase 3 CHF trial which if successful would allow it to be submitted for approval.
Happy to be corrected on this but this seems the quickest path to commercialising Revascor.
Centene obviously know what they doing by listing Revascor but...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.045(3.83%) |
Mkt cap ! $1.290B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.12 | $12.16M | 10.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 50650 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 124897 | 8 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
-0.045 ( 4.33 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.17 | $1.12 | 1447014 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| MSB (ASX) Chart |